Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Stopped early · Phase 1
Conditions studied: Carcinoma, Non-Small-Cell Lung
In brief
The objective of this trial is to study REGN4659 and cemiplimab in treatment-experienced, non-small cell lung cancer (NSCLC) patients. There are 2 phases of this study: a dose escalation phase and a dose expansion phase.
Key facts
- Study ID
- NCT03580694
- Run by
- Regeneron Pharmaceuticals
- People needed
- 17
- Starts
- 2018-06-27
- Expected to finish
- 2019-12-04
- Last updated by the study team
- 2020-03-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Regeneron Investigational Site — Chicago, Illinois, United States
- Regeneron Investigational Site — Grand Rapids, Michigan, United States
- Regeneron Investigational Site — Charlotte, North Carolina, United States
- Regeneron Investigational Site — Oklahoma City, Oklahoma, United States
- Regeneron Investigational Site — Nashville, Tennessee, United States
- Regeneron Investigational Site — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.